Allison C Hoffman1, Sarah E Evans. 1. U.S. Food and Drug Administration, Rockville, MD 20850, USA. allison.hoffman@fda.hhs.gov
Abstract
INTRODUCTION: This review identified published animal studies evaluating the possible abuse potential of acetaldehyde, nornicotine, cotinine, and anabasine based on five commonly used paradigms. These include their effects on midbrain dopamine (DA) levels, drug discrimination and substitution for known drugs of abuse, place conditioning, self-administration behavior, and somatic withdrawal symptoms. RESULTS: Acetaldehyde had mixed effects on midbrain DA levels and drug discrimination; however, it consistently produced a conditioned place preference and supported self-administration. The single available study on withdrawal found that cessation of acetaldehyde administration resulted in a somatic withdrawal syndrome. Nornicotine increased DA in the midbrain, especially in the nucleus accumbens. Although there are no data on place conditioning, it substituted for nicotine in drug discrimination testing, partially substituted for cocaine and amphetamine, and, though only a single study, supported self-administration. Anabasine increased midbrain DA levels and that it partially substituted for nicotine in drug discrimination testing. Cotinine increased midbrain DA levels and substituted for nicotine. CONCLUSIONS: The existing literature suggests that acetaldehyde and nornicotine likely possess abuse potential, with anabasine having possible abuse potential. Although some cotinine data were available, it was insufficient to draw conclusions about possible abuse potential. Further research is needed to determine the role of minor alkaloids on tobacco dependence.
INTRODUCTION: This review identified published animal studies evaluating the possible abuse potential of acetaldehyde, nornicotine, cotinine, and anabasine based on five commonly used paradigms. These include their effects on midbrain dopamine (DA) levels, drug discrimination and substitution for known drugs of abuse, place conditioning, self-administration behavior, and somatic withdrawal symptoms. RESULTS:Acetaldehyde had mixed effects on midbrain DA levels and drug discrimination; however, it consistently produced a conditioned place preference and supported self-administration. The single available study on withdrawal found that cessation of acetaldehyde administration resulted in a somatic withdrawal syndrome. Nornicotine increased DA in the midbrain, especially in the nucleus accumbens. Although there are no data on place conditioning, it substituted for nicotine in drug discrimination testing, partially substituted for cocaine and amphetamine, and, though only a single study, supported self-administration. Anabasine increased midbrain DA levels and that it partially substituted for nicotine in drug discrimination testing. Cotinine increased midbrain DA levels and substituted for nicotine. CONCLUSIONS: The existing literature suggests that acetaldehyde and nornicotine likely possess abuse potential, with anabasine having possible abuse potential. Although some cotinine data were available, it was insufficient to draw conclusions about possible abuse potential. Further research is needed to determine the role of minor alkaloids on tobacco dependence.
Authors: Brandon J Hall; Corinne Wells; Cheyenne Allenby; Mung Yan Lin; Ian Hao; Lindsey Marshall; Jed E Rose; Edward D Levin Journal: Pharmacol Biochem Behav Date: 2014-02-21 Impact factor: 3.533
Authors: Laura E Rupprecht; Tracy T Smith; Rachel L Schassburger; Deanne M Buffalari; Alan F Sved; Eric C Donny Journal: Curr Top Behav Neurosci Date: 2015
Authors: Edward D Levin; Ian Hao; Dennis A Burke; Marty Cauley; Brandon J Hall; Amir H Rezvani Journal: J Psychopharmacol Date: 2014-08-13 Impact factor: 4.153
Authors: M De Biasi; I McLaughlin; E E Perez; P A Crooks; L P Dwoskin; M T Bardo; P R Pentel; D Hatsukami Journal: Drug Alcohol Depend Date: 2014-06-02 Impact factor: 4.492
Authors: Alan F Sved; Eric C Donny; Tracy T Smith; Rachel L Schassburger; Deanne M Buffalari Journal: Exp Clin Psychopharmacol Date: 2014-07-07 Impact factor: 3.157
Authors: Tracy T Smith; Matthew B Schaff; Laura E Rupprecht; Rachel L Schassburger; Deanne M Buffalari; Sharon E Murphy; Alan F Sved; Eric C Donny Journal: Drug Alcohol Depend Date: 2015-07-13 Impact factor: 4.492
Authors: B Levi Bolin; Joseph L Alcorn; Anna R Reynolds; Joshua A Lile; Craig R Rush Journal: Exp Clin Psychopharmacol Date: 2016-08 Impact factor: 3.157